Quinolinic acid in children with congenital hyperammonemia

Area of Science:

• Neuroscience
• Biochemistry
• Pediatrics

Background:

• Congenital hyperammonemia is a metabolic disorder that can lead to severe neurological complications.
• The exact mechanisms underlying hyperammonemia-induced neuropathology are not fully understood.
• Quinolinic acid (QUIN), an excitotoxin, has been implicated in various neurological conditions.

Purpose of the Study:

• To measure QUIN levels in cerebrospinal fluid (CSF) of infants and children with congenital hyperammonemia.
• To investigate the potential role of QUIN in the neuropathology of this condition.
• To explore potential therapeutic strategies for hyperammonemic coma.

Main Methods:

• CSF samples were collected from neonates and older children diagnosed with congenital hyperammonemia.
• QUIN and neopterin levels in CSF were quantified using established biochemical assays.
• Statistical analysis was performed to compare levels between patient groups and controls.

Main Results:

• Significant elevations of QUIN (twofold to tenfold) were observed in neonates with hyperammonemic coma.
• Neopterin levels were also elevated in these neonates.
• Elevated QUIN levels were found in older children with congenital hyperammonemia, though neopterin levels were not elevated.
• QUIN levels ranged from 250-990 nM in affected neonates compared to a control mean of 110 +/- 90 nM.
• Mean QUIN levels in older children were 50 +/- 20 nM versus 17 +/- 6 nM in controls.

Conclusions:

• Findings support a significant role for quinolinic acid in the neuropathology of congenital hyperammonemia.
• Elevated QUIN may result from increased tryptophan transport or induced indolamine-2,3-dioxygenase activity.
• N-methyl-D-aspartate receptor antagonists or QUIN synthesis inhibitors show potential as treatments for hyperammonemic coma.